BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2794505)

  • 1. DBA/2J and DBA/2Ha lymphocytes differ in their ability to induce graft-vs-host disease.
    Fast LD
    J Immunol; 1989 Oct; 143(8):2489-93. PubMed ID: 2794505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a single non-H-2 gene regulating graft-versus-host disease response.
    Fast LD
    J Immunol; 1990 Jun; 144(11):4177-82. PubMed ID: 2111342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine graft-versus-host disease in an F1-hybrid model using IFN-gamma gene knockout donors.
    Ellison CA; Fischer JM; HayGlass KT; Gartner JG
    J Immunol; 1998 Jul; 161(2):631-40. PubMed ID: 9670937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and characterization of IL-2-activated veto cells.
    Fast LD
    J Immunol; 1992 Sep; 149(5):1510-5. PubMed ID: 1354678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection from lethal graft-vs.-host disease by donor stem cell repopulation.
    Rozendaal L; Pals ST; Melief CJ; Gleichmann E
    Eur J Immunol; 1992 Feb; 22(2):575-9. PubMed ID: 1347016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro characterization of a murine recipient anti-donor effector cell responsible for the development of chronic graft-versus-host disease.
    Fast LD
    J Immunol; 1991 Sep; 147(6):1731-8. PubMed ID: 1909729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
    J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A locus on chromosome 2 influences the development of acute graft-versus-host disease in a murine model.
    Harper JM; Slayback DL; Dobkins JA; Allen RD
    Bone Marrow Transplant; 1999 Jun; 23(11):1183-90. PubMed ID: 10382959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic factors influencing the development of chronic graft-versus-host disease in a murine model.
    Slayback DL; Dobkins JA; Harper JM; Allen RD
    Bone Marrow Transplant; 2000 Nov; 26(9):931-8. PubMed ID: 11100271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential cytokine expression in acute and chronic murine graft-versus-host-disease.
    Allen RD; Staley TA; Sidman CL
    Eur J Immunol; 1993 Feb; 23(2):333-7. PubMed ID: 8436168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lethal graft-vs-host disease induced by a class II MHC antigen only disparity is not mediated by cytotoxic T cells.
    Thiele DL; Bryde SE; Lipsky PE
    J Immunol; 1988 Nov; 141(10):3377-82. PubMed ID: 3053897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosuppressor- and allohelper-T cells in acute and chronic graft-vs-host disease. IV. Activation of donor allosuppressor cells is confined to acute GVHD.
    Pals ST; Radaszkiewicz T; Gleichmann E
    J Immunol; 1984 Apr; 132(4):1669-78. PubMed ID: 6230390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymic hormone modulation of age-induced changes in the induction of graft-versus-host disease by DBA/2J lymphocytes.
    Fast LD; Kouttab NM; Badamchian M; Goldstein AL
    Cell Immunol; 1990 Nov; 131(1):232-41. PubMed ID: 2225080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease.
    Williamson E; Garside P; Bradley JA; More IA; Mowat AM
    J Immunol; 1997 Aug; 159(3):1208-15. PubMed ID: 9233615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attempts at standardization of lupus-like graft-vs-host disease: inadvertent repopulation by DBA/2 spleen cells of H-2-different nonirradiated F1 mice.
    Van Rappard-Van Der Veen FM; Radaszkiewicz T; Terraneo L; Gleichmann E
    J Immunol; 1983 Jun; 130(6):2693-701. PubMed ID: 6602176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer activity in (C57BL/6 X DBA/2)F1 hybrids undergoing acute and chronic graft-vs.-host reaction.
    Pattengale PK; Ramstedt U; Gidlund M; Orn A; Axberg I; Wigzell H
    Eur J Immunol; 1983 Nov; 13(11):912-9. PubMed ID: 6641788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Keratinocytes synthesize Ia antigen in acute cutaneous graft-vs-host disease.
    Breathnach SM; Katz SI
    J Immunol; 1983 Dec; 131(6):2741-5. PubMed ID: 6417231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.